Rho GTPase-Activating Protein 45 (ARHGAP45) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Rho GTPase-Activating Protein 45 (ARHGAP45) Immunogen: Mouse HMHA1 expressed in E. coli. |
| Host | Rabbit |
| Reactivity | Mouse |
| Assay Type | Concentration: 1 mg/ml |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | IHC |
| Buffer | PBS, pH 7.4, containing 0.02% NaN3, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q3TBD2 |
| Background | Antibody anti-ARHGAP45 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Related Products
ARHGAP45 antibody
GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Ver Producto
Rho GTPase Activating Protein 45 (ARHGAP45) Antibody
Histocompatibility (Minor) Ha-1 Antibody is a Rabbit Polyclonal antibody against Histocompatibility (Minor) Ha-1.
Ver Producto
Rho GTPase-Activating Protein 45 (ARHGAP45) Antibody
ARHGAP45 Antibody is a Rabbit Polyclonal against ARHGAP45.
Ver Producto